Eli Lilly says its Covid treatment could be ready for use as soon as September

Eli Lilly and Co could have a drug specifically designed to treat Covid-19 authorised for use as early as September if all goes well with either of two antibody therapies it is testing, its chief scientist told Reuters on Wednesday.

Lilly is also doing preclinical studies of a third antibody treatment for the illness caused by the new coronavirus that could enter human clinical trials in the coming weeks, said Chief Scientific Officer Daniel Skovronsky. Lilly has already launched human trials with two of the experimental therapies.

The drugs belong to a class of biotech medicines called monoclonal antibodies widely used to treat cancer, rheumatoid arthritis and many other conditions. A monoclonal antibody drug developed against Covid-19 is likely to be more effective than repurposed medicines currently being tested against the virus.


Skovronsky said the therapies could beat a vaccine to widespread use as a Covid-19 treatment, if they prove effective.

“For the treatment indication, particularly, this could go pretty fast,” he said. “If in August or September we're seeing the people who got treated are not progressing to hospitalisation, that would be powerful data and could lead to emergency use authorisation.”